# EDGAR Filing Document

**Accession Number:** 0001131399
**File Stem:** 0001999371-26-011448
**Filing Date:** 2026-5
**Character Count:** 5399
**Document Hash:** d7136b608562010762780cc168bb92d0
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001999371-26-011448.hdr.sgml**: 20260526

**ACCESSION NUMBER**: 0001999371-26-011448

**CONFORMED SUBMISSION TYPE**: SD

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20260526

**DATE AS OF CHANGE**: 20260526

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** GSK plc
- **CENTRAL INDEX KEY:** 0001131399
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** X0

**FILING VALUES:**
- **FORM TYPE:** SD
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-15170
- **FILM NUMBER:** 261019922

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 79 NEW OXFORD STREET
- **CITY:** LONDON
- **PROVINCE COUNTRY:** X0
- **ZIP:** WC1A 1DG
- **BUSINESS PHONE:** 44 20 8047 5000

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 79 NEW OXFORD STREET
- **CITY:** LONDON
- **PROVINCE COUNTRY:** X0
- **ZIP:** WC1A 1DG

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** GSK PLC
- **DATE OF NAME CHANGE:** 20220516

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** GLAXOSMITHKLINE PLC
- **DATE OF NAME CHANGE:** 20010105

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, DC 20549**

------

**FORM SD**

------

**SPECIALIZED DISCLOSURE REPORT**

**GSK plc**

(Exact name of Registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **England and Wales** | **001-15170** | **98-0607772** |
| (State or other jurisdiction<br> of incorporation) | (Commission File Number) | (I.R.S. Employer<br> Identification No.) |

---

**GSK plc**

79 New Oxford Street

London, WC1A 1DG

United Kingdom

(Address of principal executive offices)

**Victoria Whyte**

**Company Secretary**

**+44 20 8047 5000**

(Name and telephone number of this person to contact in connection with this report)

Check the appropriate box to indicate the rule pursuant to which this form is being filed:

☒ Rule 13p-l under the Securities Exchange Act (17 CFR240.13p-l) for the reporting period from
January 1 to December 31, 2025.

☐ Rule 13q-1 under the Securities Exchange Act (17 CFR 240.13q-1) for the fiscal year ended ______.

**Section 1 – Conflict Minerals Disclosure**

**Item 1.01 Conflict Minerals Disclosure and Report**

Rule 13p-1 under the Securities Exchange Act of 1934, as amended, (the "Rule") generally provides that a company must file a specialized disclosure report if it manufactures or contracts to manufacture products for which one or more of the following minerals are necessary to the functionality or production of the company's products: cassiterite; columbite-tantalite (coltan); and wolframite; their derivatives tantalum, tin, and tungsten; and gold (collectively, "3TGs"). These are considered "conflict minerals" under the Rule regardless of their geographic origin and whether or not they fund armed conflict in the Democratic Republic of the Congo or its neighboring countries (the "covered countries").<br>GSK is a global biopharma company which prevents and treats disease with specialty medicines, vaccines and general medicines. GSK focuses on science of the immune system and advanced technologies investing in four core therapeutic areas: respiratory, immunology and inflammation; oncology; HIV; and infectious diseases to significantly impact health at scale.<br>Pursuant to the Rule, we conducted in good faith a technical review of GSK's products and surveyed our suppliers and contract manufacturing organizations ("CMOs"). This review and survey was updated via ongoing monitoring for calendar year 2025 to determine whether 3TGs were present in our products. For those products that did contain 3TGs, we conducted in good faith a reasonable country of origin inquiry that GSK believes was reasonably designed to determine whether any 3TG necessary to the functionality or production of these materials or products originated in the covered countries or was not from recycled or scrap sources. For any materials or products containing 3TGs, we requested information from the applicable suppliers and CMOs regarding the source of such 3TGs. None of the suppliers or CMOs indicated to us that any 3TGs contained in the materials or products they provided to GSK in 2025 came from the covered countries or were not from recycled or scrap sources.<br>In summary, as a result of our diligence on the suppliers and CMOs, we have no reason to believe that any of the 3TGs contained in our 2025 products that are within the scope of the Rule originated in the covered countries or were not from recycled or scrap sources.<br>The information in this Form SD is also publicly available on our website at www.gsk.com/en-gb/company/codes-standards-and-reports/#conflict-minerals-report. <br>

**Item 1.02 Exhibit**

Not applicable.

**Section 2 – Resource Extraction Issuer Disclosure**

**Item 2.01 Resource Extraction Issuer Disclosure and Report**

Not applicable.

**Section 3 – Exhibits**

**Item 3.01 Exhibits**

Not applicable.

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the duly authorized undersigned.

---

| | |
|:---|:---|
|  | /s/ Julie Brown |
| Dated: May 26, 2026 | Name: Julie Brown |
|  | Title: Chief Financial Officer |

---